| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1701-2163(15)30417-5 |
| P698 | PubMed publication ID | 25574681 |
| P2093 | author name string | Paul Claman | |
| Doron Shmorgun | |||
| Shannon Corbett | |||
| REPRODUCTIVE ENDOCRINOLOGY INFERTILITY COMMITTEE | |||
| SPECIAL CONTRIBUTOR | |||
| P2860 | cites work | GnRH agonist for triggering of final oocyte maturation: time for a change of practice? | Q28308094 |
| Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review | Q30877789 | ||
| Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis | Q33308480 | ||
| Role of vascular endothelial growth factor in ovarian physiology and pathology | Q34023513 | ||
| Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). | Q34183801 | ||
| The diagnosis and management of ovarian hyperstimulation syndrome | Q34232561 | ||
| Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome | Q34288567 | ||
| Preventive attitude of physicians to avoid OHSS in IVF patients | Q34451117 | ||
| Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model | Q34556267 | ||
| Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome | Q34589955 | ||
| Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction | Q34590985 | ||
| Regulation of vascular permeability by vascular endothelial growth factors. | Q35127972 | ||
| Ovarian hyperstimulation syndrome | Q35493429 | ||
| Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization | Q35917783 | ||
| Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment | Q36336684 | ||
| A systematic review and meta-analysis of randomized controlled trials on metformin co-administration during gonadotrophin ovulation induction or IVF in women with polycystic ovary syndrome | Q36383123 | ||
| Coasting for the prevention of ovarian hyperstimulation syndrome: much ado about nothing? | Q36405993 | ||
| Review of the evidence base of strategies to prevent ovarian hyperstimulation syndrome | Q36847973 | ||
| How to avoid ovarian hyperstimulation syndrome: a new indication for dopamine agonists | Q37465405 | ||
| Slow freezing, vitrification and ultra-rapid freezing of human embryos: a systematic review and meta-analysis | Q37683955 | ||
| A randomized controlled study of human Day 3 embryo cryopreservation by slow freezing or vitrification: vitrification is associated with higher survival, metabolism and blastocyst formation | Q38389752 | ||
| Ovarian hyperstimulation syndrome: an update review. | Q38645691 | ||
| Diagnosis, prevention and management of ovarian hyperstimulation syndrome. | Q40405808 | ||
| Agonist trigger: what is the best approach? Agonist trigger with vitrification of oocytes or embryos | Q41606675 | ||
| The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor | Q42468683 | ||
| Low-dose human chorionic gonadotropin versus estradiol/progesterone luteal phase support in gonadotropin-releasing hormone agonist–triggered assisted reproductive technique cycles: understanding a new approach | Q42950977 | ||
| Influence of body mass index and self-administration of hCG on the outcome of IVF cycles: a prospective cohort study | Q43759709 | ||
| Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertil | Q44582470 | ||
| Transcapillary fluid dynamics during ovarian stimulation for in vitro fertilization | Q45773434 | ||
| Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome. | Q46035893 | ||
| 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study | Q46129525 | ||
| Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study | Q46199929 | ||
| GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study | Q46370791 | ||
| Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups | Q46386315 | ||
| Complications of medically assisted conception in 3,500 cycles | Q46415299 | ||
| A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists | Q46568123 | ||
| Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome | Q46592157 | ||
| In vitro fertilization cycle outcome after coasting in gonadotropin-releasing hormone (GnRH) agonist versus GnRH antagonist protocols | Q46717670 | ||
| Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles | Q46901926 | ||
| Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study | Q46962402 | ||
| A prospective, randomized, controlled study to compare two doses of recombinant human chorionic gonadotropin in serum and follicular fluid in woman with high body mass index | Q48712882 | ||
| The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective | Q48794248 | ||
| Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction | Q48794435 | ||
| An ounce of prevention: outpatient management of the ovarian hyperstimulation syndrome | Q48894982 | ||
| Elective cryopreservation of all pronucleate embryos in women at risk of ovarian hyperstimulation syndrome: efficiency and safety | Q48916506 | ||
| Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization | Q48919257 | ||
| Withholding gonadotropin administration is an effective alternative for the prevention of ovarian hyperstimulation syndrome. | Q48960418 | ||
| Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study | Q59676551 | ||
| Do women with ovaries of polycystic morphology without any other features of PCOS benefit from short-term metformin co-treatment during IVF? A double-blind, placebo-controlled, randomized trial | Q61478944 | ||
| Severe ovarian hyperstimulation syndrome: a reevaluated therapeutic approach | Q69587399 | ||
| Risk factors and prognostic variables in the ovarian hyperstimulation syndrome | Q70396369 | ||
| An autopsy case of ovarian hyperstimulation syndrome with massive pulmonary edema and pleural effusion | Q73969739 | ||
| Serum oestradiol and beta-HCG measurements after day 3 or 5 embryo transfers in interpreting pregnancy outcome | Q79154563 | ||
| P433 | issue | 11 | |
| P304 | page(s) | 1024-1033 | |
| P577 | publication date | 2014-11-01 | |
| P1433 | published in | Journal of Obstetrics and Gynaecology Canada | Q15761143 |
| P1476 | title | The prevention of ovarian hyperstimulation syndrome | |
| P478 | volume | 36 |
| Q89082304 | Combined Cabergoline and Metformin in Patients with Polycystic Ovarian Disease with Hyperprolactinemia: Methodological Concerns |
| Q46820043 | Efficacy of Combined Cabergoline and Metformin Compared to Metformin Alone on Cycle Regularity in Patients with Polycystic Ovarian Disease with Hyperprolactinemia: A Randomized Clinical Trial |
| Q36263162 | Evaluation of intravenous hydroxylethyl starch, intravenous albumin 20%, and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction |
| Q26771340 | Fertility Protection in Female Oncology Patients: How Should Patients Be Counseled? |
| Q51739856 | Follicular aspiration versus coasting for ovarian hyper-stimulation syndrome prevention. |
| Q50046268 | Laparoscopic ovarian drilling versus GnRH antagonist combined with cabergoline as a prophylaxis against the re-development of ovarian hyperstimulation syndrome |
| Q87969781 | Multiorgan failure associated with severe ovarian hyperstimulation syndrome due to inadequate protocol optimisation: a rare but avoidable complication |
| Q92624059 | Pregnancy rates from natural and artificial cycles of women submitted to frozen embryo transfers: a metanalysis |
| Q36301761 | Progesterone administration for luteal phase deficiency in human reproduction: an old or new issue? |
| Q38892052 | The cumulative dose of gonadotropins used for controlled ovarian stimulation does not influence the odds of embryonic aneuploidy in patients with normal ovarian response |
| Q47200345 | The direct and indirect effects of kisspeptin-54 on granulosa lutein cell function. |
| Q89068261 | [Effect of serum estradiol level before progesterone administration on pregnancy outcomes of frozen-thawed embryo transfer cycles] |
| Q52774809 | [Pregnancy and obstetric outcomes of elective single versus double cleavage-stage embryo transfer]. |
Search more.